)
Vertex Pharmaceuticals (VRTX) investor relations material
Vertex Pharmaceuticals Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Pipeline and revenue outlook
2026 milestones include a Nov. 30 PDUFA decision for povetacicept in IgAN and DM1 phase II proof-of-concept data by year-end.
2027 catalysts include Q1 interim phase III AMPLITUDE data, H1 povetacicept myasthenia gravis proof-of-concept results, and midyear phase III suzetrigine data in diabetic peripheral neuropathy.
2026 non-CF revenue was projected at $500M+ from JOURNAVX and CASGEVY; PALSONIFY adds to that base, with further non-CF growth expected in 2027 alongside a solid CF outlook.
Povetacicept in IgAN
Interim results showed 52% proteinuria reduction at 36 weeks, >80% hematuria resolution, and 42% of patients reaching KDIGO guidelines.
Administration is planned once every four weeks at home via a 0.46 mL auto-injector; lower viscosity may reduce injection discomfort.
The Nov. 30, 2026 PDUFA remained on track; management expected a class-consistent label without IgG monitoring, citing serious infections of 0.5% in both drug and placebo arms.
A two-year eGFR endpoint is required in Europe and Asian markets; estimated diagnosed populations were 160,000 in the U.S., a similar number in Europe, and 1.5M–1.6M globally.
Management views the U.S. opportunity as a broader market-expansion opportunity; plans include a large disease-modifying field force and renal patient services modeled on CF support programs.
Inaxaplin in APOL1 kidney disease
Q1 2027 interim AMPLITUDE phase III data will assess eGFR slope; FDA discussions identify eGFR slope as necessary for an accelerated approval filing.
Inaxaplin inhibits >98% of APOL1; phase II showed 47.6% proteinuria reduction at 13 weeks, while AMPLIFIED showed 44% reduction in patients with baseline proteinuria of 0.3–0.7 g/g.
Management said two APOL1 variants, rather than FSGS histology, define the target population; natural-history data suggest placebo eGFR decline of 6–7 mL/min/year.
U.S. epidemiology estimates include 150,000 patients with two APOL1 alleles and modest-to-severe proteinuria without comorbidities, plus 100,000 with comorbidities such as type 2 diabetes.
Commercialization plans include physician education, genotyping initiatives, community outreach, and a likely companion diagnostic.
- IgAN launch readiness and a packed 2027 kidney, pain and CAH catalyst calendar.VRTX
UBS Global Biopharma Conference 2026 - Revenue rose 12% as new franchises broadened growth; higher costs weighed on earnings.VRTX
Q3 2026 - Povetacicept cut IgAN proteinuria 52.0%; AMPLITUDE interim data target early 2027.VRTX
American Society of Nephrology (ASN) Kidney Week 2026 - Diversified pipeline, regulatory catalysts, and new assets drive growth beyond cystic fibrosis.VRTX
12th Annual Cantor Fitzgerald Global Healthcare Conference - Diversified pipeline advances with global CF launches, renal expansion, and pivotal readouts ahead.VRTX
Morgan Stanley 24th Annual Global Healthcare Conference - Upcoming renal and pain launches, pivotal data, and global expansion drive growth outlook.VRTX
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue up 12% to $3.33B; guidance raised; $10B Crinetics acquisition announced.VRTX
Q2 2026 - $10B acquisition adds leading endocrine assets, accelerating growth and portfolio diversification.VRTX
M&A announcement - Q3 revenue up 12% to $2.77–$2.8B; guidance raised as pipeline and launches drive growth.VRTX
Q3 2024
)
)
)
)
)
)
)
)